Trade margin of the 9 non-scheduled cancer drugs capped at 30%
The new list of drugs is in continuation to the government’s efforts to curb profiteering on vital drugs
In continuation to its efforts to bring down drugs prices, India’s drug pricing regulator on Wednesday capped the prices of 9 non-scheduled cancer drugs by up to 87%, capping their trade margin at 30%.
The National Pharmaceutical Pricing Authority (NPPA) under the ministry of chemicals and fertilizers has put out the list of 9 anti-cancer non scheduled medicines whose MRPs have been cut by up to 87 %.
The new list of drugs is in continuation to the government’s efforts to curb profiteering on these vital drugs. In February this year, the government had capped 42 cancer drugs at 30%. The move was expected to reduce prices of cancer drugs by 85% and covered 72 formulations and 355 brands. According to the government, the price cut was expected to benefit about 22 lakh cancer patients in India and would result in annual savings of around ₹800 crore to the patients.
The NPPA has approved a formula which restricts the trade margin of the selling price by up to 30%.
The NPPA currently fixes price of drugs on the National List of Essential Medicines under schedule-I of DPCO. So far, around 1,000 drugs have been price-capped through this mode.
The trade margin rationalisation has been rolled out as proof of concept, stressing on the new paradigm of self-regulation by the industry.